Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Oktober 2025 08:00 ET | Quelle: DEBRA Research gGmbH

DEBRA Research Invests in Eliksa Therapeutics to Advance ELK-003, a Biological Eye Drop for Epidermolysis Bullosa-Related Ocular Complications

The financing supports Eliksa’s clinical development of ELK-003, a biological eye drop for ocular complications in Epidermolysis bullosa (EB) patients.The ongoing pilot study in cooperation with DEBRA...
28. Mai 2025 03:00 ET | Quelle: DEBRA Research gGmbH

DEBRA Research and Dermaliq Enter into a Strategic Collaboration to Advance Cutaneous Drug Delivery for Epidermolysis Bullosa

Initial programs will focus on developing innovative topical treatments and drug therapies for wound healing and itch relief, plus prophylactic therapies for people with Epidermolysis...
29. April 2025 04:00 ET | Quelle: DEBRA Research gGmbH

DEBRA Research Announces Impact Investment into Nova Anchora to Advance Protein Therapy for Epidermolysis Bullosa

Additional investors include global investment firm Viking Global Investors, charity foundation CureEB, the Epidermolysis Bullosa Medical Research Foundation (EBMRF), and Stanford University. The...